Malignant Pleural Mesothelioma Mpm Pipeline Insight

DelveInsight’s, “Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant Pleural Mesothelioma (MPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Malignant Pleural Mesothelioma (MPM) Understanding

Malignant Pleural Mesothelioma (MPM): Overview

Malignant pleural mesothelioma is a cancer that develops in the pleura, the thin tissue lining the lungs. Symptoms of pleural mesothelioma include chest pain, coughing and pleural effusion. The cause of pleural mesothelioma is exposure to asbestos fibers, which a person can inhale into the lungs. Diagnosis of malignant pleural mesothelioma includes multiple tests such as an X-ray or CT scan, blood tests, and biopsy to verify a malignant pleural mesothelioma diagnosis. The standard pleural mesothelioma treatment options include surgery, radiation therapy and chemotherapy. Emerging treatments include novel therapies such as immunotherapy, gene therapy and photodynamic therapy to treat pleural mesothelioma.


"Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Pleural Mesothelioma (MPM) pipeline landscape is provided which includes the disease overview and Malignant Pleural Mesothelioma (MPM) treatment guidelines. The assessment part of the report embraces, in depth Malignant Pleural Mesothelioma (MPM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Pleural Mesothelioma (MPM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Malignant Pleural Mesothelioma (MPM) R&D. The therapies under development are focused on novel approaches to treat/improve Malignant Pleural Mesothelioma (MPM).

Malignant Pleural Mesothelioma (MPM) Emerging Drugs Chapters

This segment of the Malignant Pleural Mesothelioma (MPM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Malignant Pleural Mesothelioma (MPM) Emerging Drugs


REIC gene therapy: Momotaro-Gene

REIC gene therapy is a novel investigational gene therapy with unique dual mechanisms of action. The drug candidate leverages the company’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. The drug is in Phase II clinical studies for the treatment of Malignant Pleural Mesothelioma (MPM).


ONCOS-102: Targovax

ONCOS-102 is an experimental adenovirus-based cancer therapy. The drug is in Phase II clinical studies for the treatment of Malignant Pleural Mesothelioma (MPM). In January 2015, the US FDA granted orphan drug designation to ONCOS 102 for the treatment of malignant mesothelioma.

Further product details are provided in the report……..

Malignant Pleural Mesothelioma (MPM): Therapeutic Assessment

This segment of the report provides insights about the different Malignant Pleural Mesothelioma (MPM) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Malignant Pleural Mesothelioma (MPM)

There are approx. 20+ key companies which are developing the therapies for Malignant Pleural Mesothelioma (MPM). The companies which have their Malignant Pleural Mesothelioma (MPM) drug candidates in the most advanced stage, i.e. Phase II include, Targovax.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Malignant Pleural Mesothelioma (MPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Pleural Mesothelioma (MPM): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Malignant Pleural Mesothelioma (MPM) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Pleural Mesothelioma (MPM) drugs.

Malignant Pleural Mesothelioma (MPM) Report Insights

  • Malignant Pleural Mesothelioma (MPM) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Malignant Pleural Mesothelioma (MPM) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Malignant Pleural Mesothelioma (MPM) drugs?
  • How many Malignant Pleural Mesothelioma (MPM) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Pleural Mesothelioma (MPM)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Mesothelioma (MPM) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Malignant Pleural Mesothelioma (MPM) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Malignant Pleural Mesothelioma (MPM): Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Malignant Pleural Mesothelioma (MPM) – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

NGR-TNF: MolMed

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

REIC gene therapy: Momotaro-Gen

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

HSV 1716: Virttu Biologics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Malignant Pleural Mesothelioma (MPM) Key Companies

Malignant Pleural Mesothelioma (MPM) Key Products

Malignant Pleural Mesothelioma (MPM)- Unmet Needs

Malignant Pleural Mesothelioma (MPM)- Market Drivers and Barriers

Malignant Pleural Mesothelioma (MPM)- Future Perspectives and Conclusion

Malignant Pleural Mesothelioma (MPM) Analyst Views

Appendix

List of Table

Table 1: Total Products for Malignant Pleural Mesothelioma (MPM)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Malignant Pleural Mesothelioma (MPM)

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Momotaro-Gene

• Ys Therapeutics

• MedImmune

• TCR2 Therapeutics

• Atara Biotherapeutics

• Inhibrx

• Eisai

• Targovax

• Merck & Co

• Bayer HealthCare

• SELLAS Life Sciences Group

• CanBas

• Johnson & Johnson

• Sumitomo Dainippon Pharma Oncology

• FKD Therapies

• Virttu Biologics

• MolMed

  • Tags:
  • Malignant Pleural Mesothelioma (MPM...
  • Malignant Pleural Mesothelioma (MP...
  • Malignant Pleural Mesothelioma (MP...
  • Malignant Pleural Mesothelioma (MP...
  • Malignant Pleural Mesothelioma (MP...
  • Malignant Pleural Mesothelioma (MP...
  • Malignant Pleural Mesothelioma (MP...
  • Malignant Pleural Mesothelioma (MP...

Forward to Friend

Need A Quote